Concepedia

Jonathan D. Low

JD

Statistics

Publications

3

Citations

764

H-Index

3

Active since

2017

Affiliations

Amgen (United States)(Current)

Jonathan D. Low is an author at Amgen (United States) specializing in medicinal chemistry, drug discovery, and enzyme inhibition.

Publications per year

2017–2019

3

Publications

3

Discovery of a Covalent Inhibitor of KRAS<sup>G12C</sup> (AMG 510) for the Treatment of Solid Tumors

Brian A. Lanman, Jennifer R. Allen, John G. Allen et al. · Journal of Medicinal Chemistry · 2019 · 722 citations · Full text

, , +16

Diastereoselective synthesis of fused cyclopropyl-3-amino-2,4-oxazine β-amyloid cleaving enzyme (BACE) inhibitors and their biological evaluation

Jonathan D. Low, Michael D. Bartberger, Yuan Cheng et al. · Bioorganic & Medicinal Chemistry Letters · 2018 · 23 citations · Full text

, , +15

Development of 2-aminooxazoline 3-azaxanthene β-amyloid cleaving enzyme (BACE) inhibitors with improved selectivity against Cathepsin D

Jonathan D. Low, Michael D. Bartberger, Kui Chen et al. · MedChemComm · 2017 · 19 citations · Full text

, , +13

1–3 of 3